CL2020003022A1 - Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso - Google Patents

Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso

Info

Publication number
CL2020003022A1
CL2020003022A1 CL2020003022A CL2020003022A CL2020003022A1 CL 2020003022 A1 CL2020003022 A1 CL 2020003022A1 CL 2020003022 A CL2020003022 A CL 2020003022A CL 2020003022 A CL2020003022 A CL 2020003022A CL 2020003022 A1 CL2020003022 A1 CL 2020003022A1
Authority
CL
Chile
Prior art keywords
phenyl
difluoropropan
fluoropropyl
azetidin
pyrido
Prior art date
Application number
CL2020003022A
Other languages
English (en)
Inventor
Cheol Keun Chung
Jie Xu
Hans Iding
Kyle Clagg
Michael Dalziel
Alec Fettes
Francis Gosselin
Ngiap-Kie Lim
Andrew Mcclory
Haiming Zhang
Paroma Chakravarty
Karthik Nagapudi
Sarah Robinson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67441580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020003022(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2020003022A1 publication Critical patent/CL2020003022A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

En la presente se proveen formas sólidas, sales tales como el Compuesto B, y formulaciones de 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, procesos y síntesis de estos y métodos para su uso en el tratamiento del cáncer.
CL2020003022A 2018-06-21 2020-11-20 Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso CL2020003022A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687930P 2018-06-21 2018-06-21
US201862719896P 2018-08-20 2018-08-20

Publications (1)

Publication Number Publication Date
CL2020003022A1 true CL2020003022A1 (es) 2021-06-04

Family

ID=67441580

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003022A CL2020003022A1 (es) 2018-06-21 2020-11-20 Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso

Country Status (28)

Country Link
US (4) US10954234B2 (es)
EP (2) EP4295845A3 (es)
JP (5) JP6916969B1 (es)
KR (3) KR20240113583A (es)
CN (4) CN117946107A (es)
AU (4) AU2019290545B2 (es)
CA (1) CA3098203A1 (es)
CL (1) CL2020003022A1 (es)
CO (1) CO2020014604A2 (es)
CR (2) CR20200621A (es)
DK (1) DK3810283T3 (es)
ES (1) ES2951829T3 (es)
FI (1) FI3810283T3 (es)
HR (1) HRP20230859T1 (es)
HU (1) HUE064542T2 (es)
IL (3) IL319760A (es)
LT (1) LT3810283T (es)
MX (3) MX2020011531A (es)
PE (2) PE20211207A1 (es)
PH (1) PH12020500676A1 (es)
PL (1) PL3810283T3 (es)
PT (1) PT3810283T (es)
RS (1) RS64429B1 (es)
SG (1) SG11202012171SA (es)
SI (1) SI3810283T1 (es)
TW (3) TWI915239B (es)
UA (1) UA128114C2 (es)
WO (1) WO2019245974A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3810283T (lt) 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
MX2022010425A (es) 2020-03-06 2022-09-07 Olema Pharmaceuticals Inc Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
AU2021268195A1 (en) * 2020-05-07 2022-09-29 Recurium Ip Holdings, Llc Combinations
KR20230009390A (ko) * 2020-05-12 2023-01-17 제넨테크, 인크. Gdc-9545 및 cdk4/6 억제제를 포함하는 병용 요법을 사용한 유방암 치료
CN120665066A (zh) * 2020-05-15 2025-09-19 南京再明医药有限公司 吡咯烷类化合物及其应用
CN115916769B (zh) 2020-06-28 2024-09-10 深圳扬厉医药技术有限公司 并环吲唑类化合物
WO2022005943A2 (en) * 2020-06-30 2022-01-06 Genentech, Inc. Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety
EP4267578A4 (en) * 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
JP7846700B2 (ja) * 2021-02-16 2026-04-15 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
EP4294395B1 (en) * 2021-02-16 2025-03-26 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
WO2022177835A1 (en) * 2021-02-16 2022-08-25 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib
CN117813288A (zh) 2021-07-15 2024-04-02 西藏海思科制药有限公司 芳氨基衍生物雌激素受体调节剂及其用途
WO2023125700A1 (zh) 2021-12-28 2023-07-06 南京明德新药研发有限公司 四氢环庚吲唑化合物的盐型、晶型
CN114656444A (zh) * 2022-03-04 2022-06-24 河北松辰医药科技有限公司 一种2,2-二氟-1,3-丙基磺酸内酯的合成方法
CN119156386A (zh) 2022-04-28 2024-12-17 豪夫迈·罗氏有限公司 3-((1R,3R)-1-(2,6-二氟-4-((1-(3-氟丙基)氮杂环丁烷-3-基)氨基)苯基)-3-甲基-1,3,4,9-四氢-2H-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇酒石酸盐的固体形式
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种雌激素受体降解剂化合物及其制备方法和应用
WO2026008523A1 (en) 2024-07-02 2026-01-08 F. Hoffmann-La Roche Ag Palladium catalyzed synthesis of aminoaldehyde intermediates

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7414572L (es) 1973-12-06 1975-06-09 Endo Lab
SE455604B (sv) 1982-06-29 1988-07-25 Stiftelsen Ind Organisk Elektr Sett att framstella fenetylaminer medelst elektrokemisk reduktion
DE3639329C1 (de) 1986-11-18 1988-02-25 Heesemann Karl Masch Bandschleifmaschine
US5023342A (en) 1988-05-26 1991-06-11 Massachusetts Institute Of Technology Cyclic sulfate compounds
JPH02274209A (ja) 1989-04-17 1990-11-08 Nakano Eng Kk 給茶装置
JP3084578B2 (ja) * 1991-09-11 2000-09-04 興和株式会社 光学活性化合物の製造法
US5206377A (en) 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
EP0620222A3 (en) 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
RU14873U1 (ru) 2000-06-26 2000-09-10 Закрытое акционерное общество "Патентные услуги" Комбинированная машина непрерывного литья заготовок
WO2002062339A1 (en) 2000-12-08 2002-08-15 Smithkline Beecham Corporation Antibacterial compounds
BR0116605A (pt) * 2000-12-27 2003-09-30 Hoffmann La Roche Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
US7022856B2 (en) 2001-02-12 2006-04-04 Lilly Icos Llc. Carboline derivatives
US6951961B2 (en) 2002-05-17 2005-10-04 Marina Nikolaevna Protopopova Methods of use and compositions for the diagnosis and treatment of infectious disease
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
EP1670314A4 (en) 2003-09-05 2009-02-25 Sequella Inc METHODS AND COMPOSITIONS INCLUDE DIAMINE AS A NEW THERAPEUTIC FOR TUBERCULOSIS
JP4051398B2 (ja) 2004-03-11 2008-02-20 アクテリオン ファマシューティカルズ リミテッド テトラヒドロピリドインドール誘導体
US7601840B2 (en) 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
JP2008508356A (ja) 2004-08-02 2008-03-21 スミスクライン ビーチャム コーポレーション Ｈｐｖ感染に有用な化合物
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
ES2371773T3 (es) * 2005-06-28 2012-01-10 Fujimoto Co., Ltd. Procedimiento para la producción de un derivado de aminopentano ópticamente activo, intermedio en el procedimiento, y procedimiento para producir el intermedio.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique
WO2007077570A1 (en) 2006-01-02 2007-07-12 Hetero Drugs Limited Process for obtaining pure oseltamivir
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
EP2285808B1 (en) 2008-04-29 2013-11-20 Novartis AG Spiro-indole derivatives for the treatment of parasitic diseases
US9292307B2 (en) 2008-07-30 2016-03-22 Kyocera Corporation User interface generation apparatus
US20110195929A1 (en) 2008-08-05 2011-08-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
DE102009006545B4 (de) 2009-01-29 2017-08-17 Epcos Ag Überspannungsableiter und Anordnung von mehreren Überspannungsableitern zu einem Array
WO2010107485A1 (en) 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
TW201100428A (en) 2009-03-31 2011-01-01 Arqule Inc Substituted indolo-piperidine compounds
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
WO2010138706A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US20130171103A1 (en) 2010-05-27 2013-07-04 Ptc Therapeutics, Inc. Methods for treating viral conditions
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2819299A1 (en) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2013142770A1 (en) 2012-03-23 2013-09-26 Codexis, Inc. Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
EP3578557B1 (en) 2012-03-23 2023-09-20 Novartis AG Chemical process for preparing spiroindolones and intermediates thereof
EP2682119A1 (en) 2012-07-03 2014-01-08 Université Libre de Bruxelles Aromatic N-heterocycle derivatives for use as medicine
EP2738173A1 (en) 2012-11-28 2014-06-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Heterocyclic compounds as inhibitors of the sodium iodide symporter
SI2997033T1 (en) 2013-05-17 2018-04-30 Merck Sharp & Dohme Corp. FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS
AP2015008858A0 (en) 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
ES2769780T3 (es) 2013-10-28 2020-06-29 Univ Drexel Tratamientos novedosos para los trastornos de atención y cognitivos y para la demencia asociada a un trastorno neurodegenerativo
MX2016007282A (es) 2013-12-06 2016-09-07 Hoffmann La Roche Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
MA39740A (fr) 2014-03-13 2017-01-18 Hoffmann La Roche Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes
US11427600B2 (en) 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
CN107406433A (zh) 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
CN106328117A (zh) 2015-06-30 2017-01-11 芋头科技（杭州）有限公司 一种有源噪声控制系统
WO2017059139A1 (en) 2015-10-01 2017-04-06 Olema Pharmaceuticals, Inc. TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
DK3412667T3 (da) * 2016-02-01 2022-01-10 Takeda Pharmaceuticals Co Cokrystal
CN109362222B (zh) 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
CN109843882A (zh) * 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CN109311876B (zh) * 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
CR20190379A (es) * 2017-01-30 2019-10-21 Astrazeneca Ab Moduladores del receptor de estrógeno
LT3810283T (lt) 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti

Also Published As

Publication number Publication date
AU2025263874A1 (en) 2025-11-27
AU2023229513A1 (en) 2023-10-05
EP4295845A3 (en) 2024-02-28
WO2019245974A1 (en) 2019-12-26
TWI846704B (zh) 2024-07-01
BR112020024073A2 (pt) 2021-02-17
JP7660040B2 (ja) 2025-04-10
IL319761A (en) 2025-05-01
SI3810283T1 (sl) 2023-10-30
JP2021191751A (ja) 2021-12-16
KR102564647B1 (ko) 2023-08-11
US12698284B2 (en) 2026-08-04
JP2021191750A (ja) 2021-12-16
WO2019245974A8 (en) 2020-11-05
US20240317738A1 (en) 2024-09-26
US10954234B2 (en) 2021-03-23
TW202440552A (zh) 2024-10-16
TW202016098A (zh) 2020-05-01
LT3810283T (lt) 2023-08-25
EP4295845A2 (en) 2023-12-27
KR20240113583A (ko) 2024-07-22
PT3810283T (pt) 2023-08-18
IL278063B1 (en) 2025-04-01
MX2023006785A (es) 2023-06-20
KR20210022701A (ko) 2021-03-03
US11780834B2 (en) 2023-10-10
CN118515596A (zh) 2024-08-20
DK3810283T3 (en) 2023-08-21
ES2951829T3 (es) 2023-10-25
IL278063B2 (en) 2025-08-01
CN118239948A (zh) 2024-06-25
CO2020014604A2 (es) 2020-12-10
CN117946107A (zh) 2024-04-30
IL278063A (en) 2020-11-30
MX2022016065A (es) 2023-02-02
US20240409535A1 (en) 2024-12-12
AU2019290545B2 (en) 2022-04-14
PH12020500676A1 (en) 2021-06-14
UA128114C2 (uk) 2024-04-10
KR20230117761A (ko) 2023-08-09
AU2019290545A1 (en) 2020-11-19
AU2023229513B2 (en) 2025-11-20
PL3810283T3 (pl) 2023-10-16
TW202532413A (zh) 2025-08-16
HRP20230859T1 (hr) 2023-11-10
EP3810283B1 (en) 2023-06-14
CA3098203A1 (en) 2019-12-26
US20200002331A1 (en) 2020-01-02
PE20252771A1 (es) 2025-12-22
MX2020011531A (es) 2021-03-25
TWI882617B (zh) 2025-05-01
TWI915239B (zh) 2026-02-11
EP3810283A1 (en) 2021-04-28
IL319760A (en) 2025-05-01
CN112437685A (zh) 2021-03-02
KR102682985B1 (ko) 2024-07-10
PE20211207A1 (es) 2021-07-05
US20220041587A1 (en) 2022-02-10
HUE064542T2 (hu) 2024-03-28
AU2022202967A1 (en) 2022-05-26
JP6916969B1 (ja) 2021-08-11
RS64429B1 (sr) 2023-09-29
CR20200621A (es) 2021-02-03
JP2024164006A (ja) 2024-11-26
JP2021522312A (ja) 2021-08-30
CR20230409A (es) 2023-09-25
CN112437685B (zh) 2024-08-09
FI3810283T3 (fi) 2023-08-11
JP2024054111A (ja) 2024-04-16
AU2022202967B2 (en) 2024-02-22
SG11202012171SA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CO2020014604A2 (es) Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3- il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2- difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
MX2019011693A (es) Compuestos que inhiben la proteina mcl-1.
DOP2022000051A (es) Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos
DOP2020000004A (es) Carboxamidas como moduladores de los canales de sodio
CL2021000566A1 (es) Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589)
CL2020000375A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
MX2020001302A (es) Procesos para preparar compuestos de pirrolidina.
DOP2022000042A (es) Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
MX392308B (es) Inhibidores de cinasa dependiente de ciclina 7 (cdk7).
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
CO2017009614A2 (es) Compuestos bicíclicos de sulfonamida cetona
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
GT201200147A (es) Antagonistas de espiro-oxindol de mdm2
PA8675701A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2019002583A1 (es) Inhibidores duales de magl y faah.
MX2018004868A (es) Derivados de la pirrolidina.
CL2018003109A1 (es) Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos.
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
AR114974A1 (es) Procesos para preparar compuestos tricíclicos fusionados que comprenden un resto piridinilo o fenilo sustituido, incluidos métodos para su uso
MX380255B (es) Derivados de hidroxinorketamina para el tratamiento de trastornos